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ABSTRACT: A novel pretargeted SPECT imaging strategy
based on the HaloTag enzyme has been evaluated for the first
time in a living system. To determine the efficacy of this
approach, two clinically relevant cancer biomarkers, HER2 and
TAG-72, were selected to represent models of internalizing
and noninternalizing antigens, respectively. In MDA-MB-231/
H2N (HER2-expressing) and LS174T (TAG-72-expressing)
xenograft tumors in mice, pretargeting experiments were
performed in which HaloTag-conjugated derivatives of the
antibodies trastuzumab (anti-HER2) or CC49 (anti-TAG-72)
were utilized as primary agents, and the small molecule
HaloTag ligands 111In-HTL-1, -2, and -3 were evaluated as secondary agents. While this approach was not sufficiently sensitive to
detect the internalizing HER2 antigen, pretargeting experiments involving the most optimal secondary agent, 111In-HTL-3, were
successful in detecting the noninternalizing antigen TAG-72 and provided high-contrast SPECT images at 4 and 24 h
postinjection.
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■ INTRODUCTION
Radiolabeled antibodies are frequently used in nuclear (PET/
SPECT) imaging procedures for a range of diagnostic
applications.1 The long circulatory residence times of these
high molecular weight (∼150 kDa) constructs results in high
radiation doses to patients and long waiting times before
optimal target-to-blood ratios are obtained. To overcome these
obstacles, there has been a considerable amount of recent effort
to develop alternative two-step imaging strategies, referred to
collectively as “pretargeting”.2 In this approach, an antibody
primary agent is first administered and allowed sufficient time
to reach an optimal tumor-to-blood (T/B) ratio, after which a
radiolabeled secondary agent in the form of a rapidly clearing
small molecule is then injected. Crucially, the primary and
secondary agents must be suitably designed so that they
undergo extremely rapid, selective, and, preferably, irreversible
binding at the tumor site. Due to the fast clearance of the
radioactive secondary agent from the circulation, this leads to a
lower radiation burden to the patient and T/B contrast ratios
that are comparable to or higher than those obtained by
conventional radiolabeled antibodies at much earlier time
points.
Pretargeting was originally achieved with bispecific antibodies
that have the ability to bind to both a target antigen and a
radiolabeled hapten molecule.3−5 While this approach has
demonstrated some promise in clinical settings, the suboptimal
binding affinities (∼10−10 M) that exist between the antibody
and hapten species and the high production costs of bispecific
antibodies have moderated the success of this approach. To
improve upon this method, other pretargeting strategies have
since been developed in which the primary and secondary
agents are modified with complementary reactive groups that
include (i) biotin/(strept)avidin,6−8 (ii) oligonucleotides
(particularly those based on a morpholino backbone),9−11
and, most recently, (iii) bioorthogonal copper-free click
chemistry species (particularly trans-cyclooctene/tetrazine).2,12
The most well-studied of these is the biotin/(strept)avidin
pretargeting strategy; it benefits from the extremely high
binding affinity interaction between the enzyme and its
substrate (Kd = 4 × 10
−14 M)13,14 and has out-performed
directly radiolabeled antibodies in clinical trials.15 However, this
approach has a series of important shortcomings that impact its
overall efficacy and potential for clinical translation. First, the
administration of (strept)avidin-modified antibodies can
potentially stimulate an adverse immunogenic response in
Received: March 6, 2017
Revised: April 28, 2017
Accepted: May 15, 2017
Published: May 15, 2017
Article
pubs.acs.org/molecularpharmaceutics
© 2017 American Chemical Society 2307 DOI: 10.1021/acs.molpharmaceut.7b00172
Mol. Pharmaceutics 2017, 14, 2307−2313
This is an open access article published under a Creative Commons Attribution (CC-BY)
License, which permits unrestricted use, distribution and reproduction in any medium,
provided the author and source are cited.
D
ow
nl
oa
de
d 
vi
a 
N
EW
CA
ST
LE
 U
N
IV
 o
n 
A
ug
us
t 3
0,
 2
01
8 
at
 1
3:
22
:0
2 
(U
TC
). 
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
. 
patients. Second, the presence of competing endogenous biotin
(10−7−10−8 M) is likely to partially block or even saturate the
biotin binding sites located on the primary agent, and the
presence of endogenous biotinidase would also likely result in
hydrolysis of the biotinylated agent. Lastly, the noncovalent
nature of the interaction may result in the secondary agent
gradually leaching away from the tumor site.
The reaction that occurs between the dehalogenase enzyme
HaloTag (33 kDa) and a chloroalkane HaloTag ligand (HTL;
Figure 1) is well-suited to pretargeting applications.16,17 It
proceeds with a second-order rate constant of 2.7 × 106 M−1
s−1, which is comparable to that of the biotin/(strept)avidin
reaction,16 and, importantly, it also offers a number of key
advantages. For example, the HaloTag enzyme does not suffer
interference from competing endogenous substrates, rendering
it fully available to the HTL secondary agent. Furthermore, this
enzymatic reaction also leads to the formation of a covalent
bond that effectively anchors the HTL in a precise location and
limits the possibility of detachment.
We and others have recently demonstrated the ability of this
reaction to proceed selectively in vivo by targeting HaloTag-
expressing xenograft tumors with both fluorescently labeled and
radioactive imaging agents.18−20 We have also previously
demonstrated in a series of in vitro experiments that
HaloTag-mediated pretargeting is capable of detecting elevated
expression of the cancer biomarker HER2 in a dual-modality
(SPECT/optical) approach.19 Three HTLs were developed
(111In-HTL-1, -2, and -3; Figure 1), and each was applied
successfully in these in vitro pretargeting experiments. The
lowest molecular weight secondary agent, 111In-HTL-1,
exhibited the highest overall uptake in these experiments;
however, this ligand had the highest proportion of nonspecific
uptake. More promisingly, the PEGylated secondary agents,
111In-HTL-2 and -3, revealed substantially less nonspecific
protein binding and higher specific binding to HER2-expressing
cells. In the present study, we have used these ligands to
investigate the feasibility of using the HaloTag system to enable
pretargeted SPECT imaging of HER2- and TAG-72-expressing
xenograft tumors in mice.
■ MATERIALS AND METHODS
General Methods. All reagents were purchased from
Sigma-Aldrich unless otherwise stated and were used without
further purification. Water was deionized using a Barnstead
NANOpure purification system (Thermo Scientific) and had a
resistance of >18.2 MΩ cm−1 at 25 °C. Protein concentration
measurements were made on a ND-1000 spectrophotometer
(NanoDrop Technologies, Inc.). pH was determined using pH
indicator paper (Merck Millipore). Radioactivity measurements
were made using a CRC-25R dose calibrator (Capintec, Inc.)
and a 2480 WIZARD2 or 1470 WIZARD gamma counter
(PerkinElmer).
Cell Culture. The HER2-tranfected human mammary
carcinoma cell line MDA-MB-231/H2N was a gift from Dr.
Robert Kerbel (Sunnybrook Health Sciences Centre, Toronto,
ON).21 LS174T cells were obtained from American Type
Culture Collection (ATCC). Cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Sigma),
supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 100 units/mL penicillin, and 0.1 mg/mL strepto-
mycin. All cell lines were cultured in a 37 °C environment
containing 5% CO2. Cells were harvested and passaged as
required using a trypsin−EDTA solution (Sigma). Cells were
tested and authenticated by the providers. The cumulative
length of culture was less than 6 months following retrieval
from liquid nitrogen storage.
Preparation of Trastuzumab−HTP and CC49−HTP
Primary Agents and HTL Secondary Agents. The primary
agents in this imaging strategy were the antibody−HaloTag
(Ab−HTP) conjugate proteins trastuzumab−HTP and CC49−
HTP. On the basis of the established antigen binding properties
of the unmodified antibodies, these agents were selected to
target HER2 and TAG-72 expression, respectively. Trastuzu-
mab−HTP and CC49−HTP conjugate proteins were prepared
by previously described methods using a Click&Go protein−
protein conjugation kit (Click Chemistry Tools, catalogue no.
1008).19 The HTL secondary agents 111In-HTL-1, -2, and -3
were also synthesized and assessed for radiochemical purity via
either radio-thin-layer chromatography and/or radio-HPLC
following previously described methods.19 The radiochemical
purity of these agents routinely exceeded 95%.
In Vitro Pretargeting Studies. Aliquots of 2 × 105
LS174T cells were seeded in 24-well plates in warm cell
culture medium (500 μL). The cells were allowed to adhere
overnight, and the old medium was replaced with fresh cell
culture medium (270 μL). Either unmodified HaloTag protein,
unmodified CC49, CC49−HTP, or nonspecific rabbit IgG−
HTP was added to yield a final concentration of 200 nM. The
Figure 1. HaloTag ligand secondary agents used in this work (111In-HTL-1, -2, and -3).
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cells were incubated at 37 °C for 30 min at room temperature.
The cell culture medium was removed, and the cells were
washed twice with phosphate buffered saline (PBS; pH 7.4, 500
μL). Fresh cell culture medium (400 μL) was added to each
well, and the relevant 111In-labeled HTL (25 kBq) in cell
culture medium (100 μL) was then added. The cells were
incubated for a further 30 min, 1 h, or 2 h at room temperature.
The cell culture medium was removed and combined with two
washes of PBS (pH 7.4, 500 μL). The remaining monolayer of
cells was then lysed with 0.1 M sodium hydroxide for 20 min at
room temperature. The amount of radioactivity contained
within the cell culture medium and the cell lysate fractions was
measured using a gamma counter.
In Vivo Studies. All animal procedures were performed in
accordance with the UK Animals (Scientific Procedures) Act
1986 and with local ethical committee approval. Xenograft
tumors were established in the right hind flank of female
BALB/c nu/nu mice by subcutaneous injection of 5 × 106
MDA-MB-231/H2N cells in a 1:1 mixture of fresh media and
BD Matrigel basement membrane matrix (BD Biosciences)
(100 μL) or 5 × 106 LS174T cells in sterile PBS (100 μL).
Subsequent SPECT/CT imaging and ex vivo biodistribution
experiments were performed when the tumors had reached a
volume of approximately 1 cm3.
Ex Vivo Biodistribution Experiments. Trastuzumab−
HTP (100 μg) or CC49−HTP (100 μg) in sterile PBS (100
μL) was injected into the lateral tail vein of MDA-MB-231/
H2N or LS174T-tumor-bearing mice, respectively. Following a
lag period of 24 h, the relevant 111In-labeled HTL [111In-HTL-1
(3.2 ± 0.1 MBq; 830 MBq/μmol); 111In-HTL-2 (1.7 ± 0.9
MBq; 1,170 MBq/μmol); 111In-HTL-3 (2.0 ± 1.1 MBq; 540
MBq/μmol)] was also administered via tail vein injection. Mice
were then euthanized at 4 or 24 h postinjection (p.i.) of the
HTL ligand by cervical dislocation, and selected organs, tissues,
and blood were removed. The samples were immediately rinsed
with water, dried, and transferred into a preweighed counting
tube. After weighing, the amount of radioactivity in each tube
was measured using a gamma counter. Counts per minute were
converted into radioactivity units (MBq) using calibration
curves generated from known standards. These values were
decay-corrected to the time of injection, and the percentage of
the injected dose per gram (% ID/g) of each sample was
calculated. The xenograft tissue was then cryosectioned and
analyzed by autoradiography using a Cyclone Plus phosphor
imager (PerkinElmer).
SPECT Imaging Experiments. General. SPECT images
were acquired using a four-head multipinhole nanoSPECT-CT
scanner (Bioscan, Washington, USA) that was calibrated by
imaging a phantom with an indium-111 standard solution.
Images were reconstructed using InVivoScope (Bioscan), and
analyses were performed using Inveon Research Workplace
software package version 2.2 (Siemens Preclinical Solutions).
Mice were kept under anesthesia by inhalation of 2%
isofluorane in air and maintained at 37 °C.
In Vivo Imaging of TAG-72 with Directly Radiolabeled
111In-DTPA-CC49. Mice bearing LS174T xenograft tumors were
administered 111In-DTPA−CC49 (5 MBq, 10 μg), and SPECT
images were acquired at 24, 48, and 72 h p.i.
Pretargeting Experiments. At 24 h after injection of either
trastuzumab−HTP (100 μg) or CC49−HTP (100 μg) into the
lateral tail vein, 111In-HTL-3 (3.3 ± 1.5 MBq; 600 MBq/μmol)
was also administered via tail vein injection. SPECT images
were acquired at 4 and/or 24 h p.i. of 111In-HTL-3.
Statistical Analyses. All statistical analyses and nonlinear
regression were performed using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Data were tested for normality
and analyzed either by the unpaired, two-tailed Student’s t test
where appropriate, with one- or two-way ANOVA for multiple
comparisons, or with Tukey or Bonferroni post-tests,
respectively, to calculate significance of differences between
groups. All data were obtained at least in triplicate, and the
results were reported and graphed as the mean ± standard
deviation, unless stated otherwise.
■ RESULTS
In Vitro Detection of TAG-72 via HaloTag-Mediated
Pretargeting. Both 111In-HTL-2 and -3 enabled specific
detection of TAG-72 expression on LS174T cells that had been
previously incubated with CC49−HTP (Figure 2). For each
HTL, maximum cell binding was achieved within an incubation
Figure 2. (A) In vitro pretargeting experiments involving (B) 111In-HTL-2 and (C) 111In-HTL-3 as secondary agents revealed an ability to detect
TAG-72 expression when cells were pretargeted with CC49−HTP. ***, P < 0.001.
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time of 30 min, and no release of either HTL was observed
within the 2 h time frame of this experiment. The total uptake
of 111In-HTL-2 was approximately double that of 111In-HTL-3
(1.20 ± 0.02 and 0.55 ± 0.04%, respectively). Notably,
however, 111In-HTL-3 exhibited considerably less nonspecific
protein binding, so 111In-HTL-3 gave the highest fold increase
compared with background signal (as defined by the mean
average of all negative control experiments) at all time points.
In Vivo Pretargeting of HER2-Expressing Tumors. The
results of ex vivo biodistribution experiments performed at 4 h
p.i. of the HTL secondary agents revealed that uptake of 111In-
HTL-1 and -2 was not significantly higher in the tumors of
mice administered trastuzumab−HTP compared with mice
given no primary agent (Tables S1 and S2). Uptake of 111In-
HTL-3 was elevated in tumors of mice given trastuzumab−
HTP (2.8 ± 1.0% ID/g) compared with the nonpretargeted
control group (1.2 ± 0.4% ID/g; P < 0.05); however, this did
not reach values significantly higher than those from mice
administered a nonspecific IgG−HTP primary agent (2.1 ±
0.4% ID/g) (Figure 3A,B and Table S2). SPECT images
acquired at 4 h p.i. of 111In-HTL-3 in mice that were previously
administered trastuzumab−HTP were consistent with the
biodistribution data and revealed tumors that exhibited
moderate contrast against normal tissues (Figure 3C). At 24
h p.i., most of the unbound 111In-HTL-3 in the blood pool was
either eliminated or retained within the liver; however, uptake
of 111In-HTL-3 within the tumor was still visible.
In Vivo Detection of TAG-72 Using Directly Radio-
labeled 111In-DTPA−CC49. SPECT images and ex vivo
biodistribution data revealed that uptake of 111In-DTPA−
CC49 within LS174T tumors at 24 h p.i. reached 48.2 ± 16.3%
ID/g (Figure 4A,B and Table S3). At 72 h p.i., total uptake
remained unchanged at 47.4 ± 11.2% ID/g; however,
elimination of non-tumor-bound 111In-DTPA−CC49 led to
increasing T/B and T/M ratios over this time frame and
Figure 3. (A) In vivo pretargeted imaging strategy for the detection of breast cancer biomarker HER2. (B) Values obtained from ex vivo
biodistribution experiments at 4 h p.i. of 111In-HTL-3 showing overall tumor uptake (left), radioactivity in blood (middle), and tumor-to-muscle
ratios (right). *, P < 0.05. (C) Representative coronal (upper) and transverse (lower) SPECT images of the same mouse obtained at 4 and 24 h p.i.
of 111In-HTL-3. In this case, the mouse was administered trastuzumab−HTP (Tz−HTP) 24 h prior to the administration of 111In-HTL-3. Images
intersect the center of the tumor (white dotted circle). Error bars represent the standard error of the mean.
Figure 4. (A) Representative coronal (upper) and transverse (lower) SPECT images of a BALB/c nu/nu mouse bearing a TAG-72-expressing
LS174T xenograft tumor (white dotted circles) acquired at 24, 48, and 72 h p.i. of 111In-DTPA−CC49 (5 MBq, 10 μg). (B) Values from ex vivo
biodistribution experiments performed at 24 and 72 h p.i. (C) Tumor-to-blood ratios (T/B) and (D) tumor-to-muscle ratios (T/M) obtained from
ex vivo biodistribution experiments. Error bars represent the standard error of the mean.
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reached maximum values of 5.6 ± 2.2 and 74.8 ± 26.4,
respectively (Figure 4C,D).
In Vivo Pretargeting of TAG-72-Expressing Tumors.
While 111In-HTL-2 revealed higher tumor uptake in mice that
received the CC49−HTP primary agent compared with that in
nonpretargeted control mice at 4 h p.i. (2.3 ± 0.6 and 1.2 ±
0.2% ID/g, respectively; P < 0.05), it did not exceed the values
achieved with IgG−HTP (1.9 ± 0.3% ID/g) (Figure 5A,B and
Table S4). Similarly, T/M ratios followed the same trend, as
values were greater in mice that received the CC49 primary
agent versus no primary agent (4.6 ± 0.7 and 2.3 ± 0.4; P <
0.05), but values were not greater than those from mice
administered IgG−HTP (2.7 ± 1.0) (Figure 5B). Tumor-to-
liver ratios did not differ significantly between pretargeted and
nonpretargeted mice. There was also no increase in the amount
of radioactivity within the blood, suggesting that any reaction
product formed had already been sequestered to the tumor or
cleared from the circulation within this time frame (Figure 5B).
At 24 h p.i. of 111In-HTL-2, no statistical differences in tumor
uptake were measured between any of the experimental groups
(Table S5).
The secondary agent with the lowest nonspecific protein
binding, 111In-HTL-3, reached its highest tumor uptake values
in mice that received the CC49−HTP primary agent compared
with mice administered either IgG−HTP or nonpretargeted
control mice at 4 h p.i. [3.2 ± 0.3, 2.1 ± 0.3, and 1.5 ± 0.4%
ID/g, respectively; P < 0.01) (Figure 5A,B and Table S6).
Tumor-to-muscle ratios were greater in mice that received the
CC49 primary agent compared with no primary agent (5.0 ±
1.0 and 2.3 ± 0.3, respectively; P < 0.01), but these ratios were
not greater than those from mice administered IgG−HTP (3.4
± 0.7; P = 0.088) (Figure 5B). The amount of radioactivity
within the blood was higher in the CC49−HTP pretargeted
group compared with the nonpretargeted group (10.2 ± 0.9
and 6.5 ± 2.1% ID/g, respectively; P < 0.05), which is most
likely due to the formation of the enzymatic reaction product
within the circulation, although this was not confirmed. As
expected, the blood radioactivity levels in mice administered
IgG−HTP (8.9 ± 0.8% ID/g) also appeared slightly elevated
compared with the nonpretargeted group, although it did not
reach statistical significance. As a result of the elevated uptake
of 111In-HTL-3 in the tumors of mice administered CC49−
HTP, SPECT images were obtained in which tumors were
clearly contrasted against surrounding tissues and organs,
whereas lower tumor uptake was observed in nonpretargeted
controls (Figure 5C). Autoradiography images acquired from
tumor tissue sections revealed greater uptake of 111In-HTL-3 in
the tumors of mice administered the CC49−HTP primary
agent versus no primary agent (Figure 5D). At 24 h p.i. of 111In-
HTL-3, the uptake value in mice given the CC49−HTP
primary agent (3.3 ± 0.1% ID/g; Table S7) was comparable to
that at 4 h p.i. and remained higher than nonspecific controls,
Figure 5. (A) In vivo pretargeted imaging strategy for the detection of noninternalizing antigen TAG-72. (B) Values obtained from ex vivo
biodistribution experiments at 4 h p.i. of 111In-HTL-2 (upper) and 111In-HTL-2 (lower) showing overall tumor uptake (left), radioactivity in blood
(middle), and tumor-to-muscle ratios (right). *, P < 0.05; **, P < 0.01. (C) Representative coronal (upper) and transverse (lower) SPECT images of
LS174T tumor-bearing mice obtained at 4 h p.i. of 111In-HTL-3. In this case, the mouse was administered CC49−HTP (left), no primary agent
(middle), or IgG−HTP (right) at 24 h prior to administration of 111In-HTL-3. Images intersect the center of the tumor (white dotted circle). (D)
Autoradiography images of harvested tumor tissue sections revealing higher uptake of 111In-HTL-2 and -3 in tumors of mice pretargeted with
CC49−HTP. Error bars represent the standard error of the mean.
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yet owing to the clearance of 111In-HTL-3 from the circulation
in this time frame, the tumor-to-blood contrast ratio increased
markedly from 0.3 to 1.65. The tumor-to-liver ratio was also
significantly higher in mice administered CC49−HTP (0.38 ±
0.05) compared with no pretargeting vector (0.26 ± 0.02; P <
0.05) and IgG−HTP (0.28 ± 0.05; P < 0.05).
■ DISCUSSION
We have previously shown that pretargeting experiments
involving trastuzumab−HTP and 111In-HTL-1, -2, and -3
were capable of detecting elevated expression levels of HER2 in
in vitro experiments.19 In our initial efforts to translate
HaloTag-mediated pretargeted imaging of HER2 into a living
system, we found no evidence that the smallest secondary
agents, 111In-HTL-1 and -2, reacted with the trastuzumab−
HTP primary agent either within the blood or at the tumor site.
This is most likely either due to the overly rapid elimination or
metabolism of these agents, which in both cases would limit the
possibility of reaction with HTP. More promisingly, 111In-HTL-
3 exhibited significantly higher binding to HER2-transfected
tumors pretargeted with trastuzumab−HTP compared to
nonpretargeted control experiments, although these values
were not significantly higher compared with values obtained
with a nonspecific IgG−HTP primary agent. Due to the high
molecular weight of these primary agents, a proportion of their
overall uptake in tumors (typically around 4−5% ID/g for a
whole immunoglobulin) will be attributable to the nonspecific
enhanced permeability and retention effect. As a result, modest
accumulation of Ab−HTP in tumor tissue will occur even when
it is delivered with an antibody lacking antigen specificity. As a
result, a general trend can be observed for all of the in vivo
pretargeting experiments in which 111In-HTLs reached higher
uptake values in tumors following injection of the nonspecific
IgG−HTP compared with values obtained when no primary
agent is administered. While the results of the HER2
pretargeting experiments indicate that a reaction between
111In-HTL-3 and the HaloTag enzyme occurred at the tumor,
the comparable uptake values achieved following administration
of trastuzumab−HTP and IgG−HTP suggest that this
approach was not sufficiently sensitive to allow in vivo detection
of HER2 expression. It should be noted that this model system
is particularly challenging as it is well-established that HER2
undergoes cellular internalization upon binding trastuzumab.
The rate of this internalization process (t1/2 = 11 h)
22 would
render approximately 80% of the primary agent inaccessible to
the HTL secondary agents following a 24 h lag period and
would therefore severely limit HER2-mediated uptake.
The efficacy of the HaloTag pretargeting approach was also
examined using the noninternalizing glycoprotein TAG-72,
which is overexpressed in several malignancies, including
breast,23 colorectal,24 gastric,25 lung,26 ovarian,27 and pancreatic
cancers.28,29 Its high cell surface persistence renders TAG-72 a
more promising target for pretargeting strategies compared
with HER2.30,31 The colorectal cancer cell line LS174T was
selected as the basis of an in vivo model as this cell line is
known to overexpress TAG-72, and when it is established as
subcutaneous xenograft tumors, the expression levels of this
antigen are comparable to those found in metastatic tumor
masses in patients. In vitro pretargeting experiments involving
the HaloTag-modified anti-TAG-72 antibody, CC49−HTP,
yielded promising results as both 111In-HTL-2 and -3 exhibited
significantly higher cell binding compared with nonspecific
experimental controls. While 111In-HTL-3 revealed approx-
imately 50% lower total cell binding compared with 111In-HTL-
2 (potentially as a result of its lower specific activity
formulation), 111In-HTL-3 exhibited much lower nonspecific
protein binding due to its more extensively PEGylated
structure. This general trend is consistent with our previously
reported in vitro pretargeting experiments involving HER2.19
In vivo pretargeting experiments in mice bearing TAG-72-
expressing LS174T tumors showed better efficacy compared
with the previous HER2 pretargeting experiments. In this case,
111In-HTL-3 was the best performing secondary agent as at 4 h
p.i. it accumulated to a significantly higher degree in the tumors
of mice administered CC49−HTP compared with those given
no primary agent or IgG−HTP. At 24 h after injection of 111In-
HTL-3, no further increase in tumor uptake in mice
administered CC49−HTP was observed, and these values still
exceeded nonspecific experimental controls. Furthermore, as
most of the non-tumor-bound 111In-HTL-3 was cleared from
the blood pool, this led to a large (450%) increase in the tumor-
to-blood contrast ratio and, thus, improved image quality
(Figure S1). It should, however, be recognized that, compared
with the directly labeled 111In-DTPA−CC49 antibody, this
approach has not led to an improvement of T/B contrast ratios.
While chemical possibilities to increase the efficiency of the
HaloTag reaction in vivo appear limited, additional optimization
of this pretargeting approach could feasibly lead to improve-
ments in imaging performance. In common with other
pretargeting strategies, this approach is best suited to
noninternalizing antigens as these provide greater accessibility
to the HTL secondary agents. While we have used TAG-72 as a
model system, the facile attachment of HaloTag to any
antibody of interest will enable easy transposition of this
method to other clinically relevant, noninternalizing cancer
biomarkers, such as A33.
■ CONCLUSIONS
In summary, we have demonstrated for the first time that
HaloTag-mediated pretargeted imaging of cancer biomarkers is
possible in living animals. While this approach was not
sufficiently sensitive to detect HER2 expression, it was
successful in enabling detection of the noninternalizing TAG-
72 antigen. This novel pretargeting strategy is an important
contribution to contemporary in vivo delivery systems as it
represents a new addition to a very limited collection of
chemical reactions that proceed in vivo. In addition to allowing
targeted delivery of radioisotopes for nuclear imaging
applications, the HaloTag pretargeting strategy could also be
readily modified to include therapeutic radioisotopes and
cytotoxic drugs.
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